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Different strains of simian virus 40 (SV40) exist and are associated with some human malignancies, but it is not known if SV40 strains
differ in biological potential in vivo. In two long-term experiments, Syrian golden hamsters 21 days of age were inoculated by the
intraperitoneal route with two different strains of SV40 (107 plaque-forming units/animal) and were followed for 8 or 12 months. In vivo
responses to strain VA45–54, isolated originally from monkey kidney cells, and to strain SVCPC, recovered from human cancers, were
compared. Control animals of the same age were inoculated intraperitoneally with cell culture media. Malignancies developed only in
animals infected with SV40 and not in controls. The rate of tumor development was more frequent among animals infected with strain
SVCPC than with VA45–54, both in experiments held for 8 months (11/22, 50% vs. 4/20, 20%) and for 12 months (7/15, 47% vs. 3/13,
23%). Histologically, the tumors resembled mesotheliomas, osteosarcoma, and poorly differentiated sarcomas. Metastases to lung and lymph
nodes occurred with both viral strains. T-antigen expression was detected in most tumor cells by immunohistochemistry. Anti-T-antigen
antibodies were produced by almost all tumor-bearing animals and by about two-thirds of those that did not develop tumors after virus
inoculation. SV40 viral neutralizing antibodies were detected in all tumor-bearing animals and in 92% and 38% of those inoculated with
SVCPC and VA45–54, respectively, that failed to develop tumors. Antibody titers were usually higher in animals with tumors than in those
without. Control animals did not develop viral antibodies. Infectious virus was recovered from 2 of 15 tumors tested. This study showed that
there are biological differences between these two SV40 strains that influence the outcome of infections in normal hosts, including the
development of malignancies and neutralizing antibody, and proved the principle that SV40 strains from different clades can vary in
biological properties in vivo.
D 2004 Elsevier Inc. All rights reserved.
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M.D. Anderson Cancer Center, Houston, TX 77030, USA.some human malignancies (Jasani et al., 2001; Stratton et
al., 2003; Vilchez and Butel, 2004). The prevalence of SV40
infections in humans is not known, but studies suggest that
SV40 is being transmitted in some human populations today
(Bergsagel et al., 1992; Butel et al., 1999a, 1999b; Carbone
et al., 1996; Lednicky et al., 1995, 1997; Malkin et al.,
2001; Li et al., 2002a, 2002b; Nakatsuka et al., 2003).
However, possible biological differences among viral
isolates and the dynamics of SV40 infections in humans
remain largely unknown.04) 168–177
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with the early region coding for the large (T-ag) and small
(t-ag) tumor antigens and the late region encoding the capsid
proteins VP1, VP2, and VP3. There is only one known
serotype of SV40, but recent studies have shown that viral
genetic strains exist that can be distinguished on the basis of
the viral regulatory region and the C-terminus of T-ag (Butel
and Lednicky, 1999; Stewart et al., 1996, 1998) and can be
placed into distinct genogroups (clades) (Forsman et al.,
2004). In vitro studies have indicated that differences in
those regions of the SV40 genome may be important in
virus–host interactions (Cole et al., 1979; Grodzicker et al.,
1974; Kelly and Lewis, 1973; Lednicky and Butel, 1997;
Rabson et al., 1964; Spence et al., 1990).
Most of the SV40 T-ag coding sequence is absolutely
conserved among viral isolates from monkeys and humans,
but a variable domain at the extreme C-terminus of T-ag,
defined as the last 86 amino acids of the molecule (residues
622–708), has been identified (Stewart et al., 1996, 1998).
Strains can be distinguished by nucleotide differences in this
region, including polynucleotide insertions and deletions as
well as single nucleotide changes that would alter the amino
acid sequence of the viral oncoprotein (Stewart et al., 1996,
1998). A recent phylogenetic analysis of 14 complete viral
genomes from nonhuman and human sources showed that
groupings based on the C-terminal T-ag region were highly
congruent with groupings based on the entire SV40 genome
sequence (Forsman et al., 2004). In addition, nucleotide
sequences in the small t-ag unique region and the viral
regulatory region help to distinguish SV40 strains (Stewart et
al., 1996). Laboratory-adapted monkey strains of SV40
usually contain two 72-base-pair enhancer elements; these
are designated bnonarchetypalQ or complex regulatory region
structures (Lednicky and Butel, 2001; Stewart et al., 1998).
In contrast, natural isolates of SV40 freshly recovered from
monkeys or found in human cancers generally do not contain
duplications in the enhancer (barchetypalQ or simple)
(Lednicky and Butel, 2001; Lednicky et al., 1998; Stewart
et al., 1996, 1998). These identifying characteristics of SV40
strains have established conclusively that the detection and
isolation of SV40 in human malignancies and other clinical
samples is not the result of laboratory contamination (Butel,
2001; Stewart et al., 1998; Vilchez and Butel, 2004).
A recent meta-analysis involving 1793 cancer patients
and 1649 control subjects found a significant excess risk of
SV40 associated with human primary brain cancers,
malignant mesotheliomas, bone cancers, and non-Hodgkin’s
lymphoma (Vilchez et al., 2003). Thus, the major types of
human malignancies associated with SV40 are similar to
those induced by SV40 in hamsters (Cicala et al., 1993;
Diamandopoulos, 1972, 1973; Gazdar et al., 2002; Girardi
et al., 1962). This concordance emphasizes the relevance of
the hamster model for human disease. The Institute of
Medicine of the National Academies recently concluded that
bthe biological evidence is of moderate strength that SV40
exposure could lead to cancer in humans under naturalconditionsQ and recommended btargeted biological researchQ
(Stratton et al., 2003).
It is not known if SV40 strains vary in replicative
capacity and/or oncogenic potential in vivo. The human
papillomavirus group provides the classic example of DNA
tumor virus strains that differ in oncogenic capacity. Of the
more than 75 types described, about 30 cause genital
infections, but only a few strains are associated with the
development of cervical carcinoma (Lowy and Howley,
2001). This identification of high-risk viral strains is
important, as it has led to the development of preventive
strategies against human papillomavirus type 16-associated
cervical carcinomas (Koutsky et al., 2002).
As multiple polyomavirus SV40 strains appear to be
present in the human population (Butel et al., 1999a;
Lednicky et al., 1995; Li et al., 2002a, 2002b; Stewart et
al., 1996, 1998), studies are required to address potential
differences in their biological properties. This report
describes an investigation of the biological properties of
two representative SV40 strains, one isolated from monkeys
(VA45–54) and one from human malignancies (SVCPC).
Based on phylogenetic analysis of complete SV40 genomic
sequences, these two viral strains belong to different SV40
genogroups (Forsman et al., 2004). They have nucleotide and
amino acid differences at several positions in the T-ag
variable domain, in the small t-ag unique region, and in the
regulatory region. The experiments were performed in the
Syrian golden hamster (Mesocricetus auratus) because it is
the only rodent model that is highly susceptible to SV40
infection and carcinogenesis (Cicala et al., 1993; Diamando-
poulos, 1972, 1973; Girardi et al., 1962). The results revealed
differences between the two viral strains that influenced the
development of malignancies and neutralizing antibody,
establishing the concept that viruses from different SV40
genogroups can differ in biological characteristics in vivo.Results
Oncogenicity of SV40 strains VA45–54 and SVCPC in
weanling hamsters
Weanling 21-day-old Syrian golden hamsters were
inoculated intraperitoneally with 1.0  107 plaque-forming
units of SV40 strain VA45–54 or strain SVCPC. Control
animals were inoculated with uninfected cell lysates. Two
independent experiments were carried out, 1 year apart.
Animals in Experiment I were observed for 8 months and
those in Experiment II for 12 months. A combined total of
70 hamsters were virus-inoculated and 78 lysate-inoculated
animals served as uninfected controls. Malignancies devel-
oped only among animals exposed to SV40 and not in the
control groups (Table 1).
In Experiment I, hamsters inoculated with SVCPC
developed significantly more malignancies than did ham-
sters infected with VA45–54 (11/22, 50% vs. 4/20, 20%) by
Table 1
Cancer development in hamsters infected as weanlings with SV40 strain VA45–54 and strain SVCPC
Experiment Duration of
experiment (months)
Virus No. of
animals
No. with
cancer (%)
Time to tumors (months),
median (range)
I 8 VA45–54 20 4 (20) 8 (4–8)
SVCPC 22 11 (50) 7 (4–8)
Control 45 0 (0) –
II 12 VA45–54 13 3 (23) 6 (5–7)
SVCPC 15 7 (47) 6 (5–12)
Control 33 0 (0) –
Fig. 1. Hamster neoplasm with histological characteristics of a mesothe-
lioma induced by the intraperitoneal inoculation of SV40, strain SVCPC;
stained with hematoxylin–eosin. Original magnification, 20.
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experiment by 50% to 12 months in duration, yielded
similar differences in tumor development (7/15, 47% for
SVCPC vs. 3/13, 23% for VA45–54) (Table 1). Experiment
II confirmed the reproducibility of the difference in
oncogenic potential between the two viruses and showed
that the difference did not reflect a later onset of tumors
induced by VA45–54. The median latency in months to time
of tumor appearance was approximately the same for
animals exposed to either virus.
In both groups of SV40-infected hamsters from the two
experiments, gross examination of tumor-bearing hamsters
revealed solid abdominal tumors up to 2 cm in diameter, as
well as neoplastic involvement and thickening of peritoneal
surfaces, with visceral adhesions and with invasion of
viscera, retroperitoneal and perirenal regions, and the
abdominal wall (the latter possibly from the injection site).
Six animals among the two infected groups developed
severe ascites (30–60 ml) in association with abdominal
neoplasms and visceral involvement. The ascites fluids were
positive for antibodies to SV40 T-ag by indirect immuno-
fluorescence. There were 12 cases of pleural and pulmonary
involvement with pulmonary nodules (metastasis); there
was lymph node invasion (metastasis) in several cases.
Pathology of SV40-induced tumors
Histologically, most of the tumors had features of poorly
differentiated sarcomas: sheets of plump to spindled cells
with generally indistinct cytoplasmic borders, variable
amounts of eosinophilic cytoplasm, and rounded to elongated
nuclei. Neoplastic cells had mild to profound atypia, with
bizarre multinucleated and karyomegalic cells up to 150 Am
diameter, and high mitotic rates. Four of these solid
neoplasms were osteogenic, compatible with osteosarcoma.
Several cases had areas of myocyte-like differentiation with
elongated, strap-like cells with multiple tandem nuclei and
fibrillar cytoplasm, suggestive of rhabdomyosarcoma. In 18
hamsters, neoplasms that covered and thickened peritoneal
surfaces and invaded subjacent tissues featured microscopic
exophytic proliferations supported on stalks or cores of
eosinophilic elongate-spindle cells, and covered/lined by one
to several layers of pleomorphic polyhedral-to-columnar
epithelioid cells. These lining cells had variably distinct
cytoplasmic borders, with scant-to-ample and pale-to-eosi-nophilic cytoplasm, rounded, generally vesicular nuclei, and
generally indistinct nucleoli. Among them were scattered
bizarre cells with marked karyomegaly or multiple nuclei.
Adjacent serosal surfaces were covered/lined by single to
multiple layers of cells that varied in morphology from
inconspicuous flattened cells (resembling normal mesothe-
lium) to plump, bulging columnar cells and occasional large,
bizarre cells. The histologically epithelioid areas merged with
sarcoma-like areas, resembling biphasic mesotheliomas in
humans. Frequently, it was not clear if solid nodules were
contiguous with or independent of the mesotheliomas (Fig.
1). The areas of mesenchymal differentiation in various
tumors may indicate primary osteosarcomas or rhabdomyo-
sarcomas or, alternatively, may reflect heterologous sarcom-
atous differentiation in mesotheliomas. However, considered
collectively, malignancies resulting from SV40 strains
VA45–54 and SVCPC were morphologically similar.
Expression of SV40 T-ag in hamster tumors
Necropsy tissue specimens from 15 of the SV40-induced
malignancies (4 induced by VA45–54 and 11 by SVCPC)
were assessed by immunohistochemistry for T-ag expres-
sion using antibodies against the N- (PAb416) and C-termini
(PAb101) of SV40 T-ag. The majority of the malignant cells
in the 15 neoplasias showed strong nuclear expression of T-
ag with both antibodies (Fig. 2). However, it is important to
Fig. 2. Detection of SV40 T-ag by immunohistochemistry in the hamster
malignancy shown in Fig. 1. (a, b) Cells were stained using monoclonal
antibody PAb101 (Santa Cruz Biotechnology) directed against the C-
terminus of SV40 T-ag. (c) Cells were stained with monoclonal antibody
PAb416 (Oncogene Research Products) directed against the N-terminus of
SV40 T-ag. Note that although the majority of tumor cells expressed
nuclear SV40 T-ag, there are malignant cells in the tumor that are not
expressing detectable amounts of the viral oncoprotein. Magnifications: (a)
20; (b) 40; (c) 40.
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not express detectable levels of the viral oncoprotein. This is
similar to findings with liver tumors in SV40 transgenic
mice (Sepulveda et al., 1989).
Viral-specific antibodies induced by SV40 strains VA45–54
and SVCPC in hamsters
Serologic responses to SV40 were determined for 64 of
the inoculated animals and 58 control animals (Table 2).
Results from Experiments I and II were similar, and so are
combined in Table 2. The majority of the tumor-bearinghamsters produced detectable T-ag antibodies, regardless of
the virus strain. Many of the animals that failed to develop
cancer had detectable T-ag antibody responses when the
experiments were terminated 8 and 12 months post-
inoculation, including 62% in the VA45–54 group and
69% in the SVCPC group. Similarly, virus-neutralizing
antibodies were produced by all the tumor-bearing animals
and by many of the virus-inoculated animals that failed to
develop tumors (38% in the VA45–54 group and 92% in the
SVCPC group). Overall, the titers of both T-ag antibodies
and viral neutralizing antibodies tended to be higher among
tumor-bearing animals than in animals without malignan-
cies. None of the animals tested from the control group had
serologic evidence of SV40 infection (Table 2).
Virus rescue
Attempts were made to recover infectious SV40 from 15
hamster tumor-derived cell lines as described in Materials
and methods. Virus was rescued from two tumors, one
induced by each SV40 strain. The VA45–54 tumor (a
mesothelioma/osteosarcoma) was sampled 8 months after
inoculation, whereas the SVCPC tumor (a mesothelioma)
was harvested at 4 months post-inoculation. The VA45–54
isolate was recovered from the original explanted culture of
tumor cells (P0), and SVCPC isolates were rescued from
three independent cell lines established from separate
fragments of that tumor (at passages P1 or P2).Discussion
Previous studies of the induction of malignancies by SV40
in hamsters have indicated that the process is multifactorial.
There are host-dependent factors, such as species, age
(newborn vs. weanling vs. adult), route of inoculation
(intracerebral vs. subcutaneous vs. intravenous), and target
cell type (brain, mesothelia, lymphoid, etc.) (Butel et al.,
1972; Cicala et al., 1993; Diamandopoulos, 1972, 1973;
Girardi et al., 1962). A virus-dependent factor, dose of
inoculum, is also a predictor of the development of cancer
(Gerber and Kirschstein, 1962; Girardi et al., 1963; Dia-
mandopoulos, 1973, 1978). The current study indicates that
SV40 strain distinction may represent another virus-depend-
ent factor that influences the oncogenic potential of this virus.
We have shown here that strains VA45–54 and SVCPC
reproducibly differ in frequency of tumor induction in
weanling hamsters. In addition, the oncogenic capacity of
strain SVCPC was clearly demonstrated, an important
finding as SVCPC has been recovered and detected in several
human malignancies (Arrington et al., 2004; Krieg et al.,
1981; Lednicky et al., 1995; Vilchez et al., 2002a, 2002b).
Based on these findings, it will be possible to design
approaches to identify genetic regions of the viral genome
that contain determinants of SV40 oncogenic potential.
Strains VA45–54 and SVCPC differ in three genomic
Table 2
Antibody responses to SV40 in Syrian golden hamsters inoculated intraperitoneally as weanlings with strains VA45–54 and SVCPCa
Group Tumors No. tested Anti-T-antigenb Neutralizing antibodyb
No. positive (%) Titerc, median (range) No. positive (%) Titerc, median (range)
VA45–54 Yes 7 7 (100) 1000 (50–5000) 7 (100) 1000 (1000–2000)
No 26 16 (62) 10 (5–5000) 10 (38) 200 (10–1000)
Totals 33 23 (70) 17 (52)
SVCPC Yes 18 17 (94) 100 (10–5000) 18 (100) 1000 (100–20,000)
No 13 9 (69) 10 (5–50) 12 (92) 200 (10–1000)
Totals 31 26 (84) 30 (97)
Controls No 58 0 (0) 0d (0)
a Sera were collected when tumor-bearing animals were sacrificed or when the experiments were terminated at 8 months and 12 months after inoculation.
Results from Experiment I and Experiment II are combined in this table.
b Indirect immunofluorescence was performed to detect antibodies against SV40 T-ag and a specific plaque-reduction assay was used to measure neutralizing
antibodies against SV40.
c Titers expressed as reciprocal of highest serum dilution that tested positive. Median titers given are for positive sera only.
d n = 19 samples tested.
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tide and amino acid differences in the variable domain at the
C-terminus of T-ag (residues 622–708) (Forsman et al.,
2004; Stewart et al., 1996, 1998) and strains VA45–54 and
SVCPC differ in this region by four amino acids. The
function of the variable domain is not known, but embedded
within it between amino acids 682 and 708 is the host range/
adenovirus (Ad) helper function (hr/hf) domain. T-ag C-
terminal deletion mutants exhibited different growth proper-
ties in several monkey cell lines (hr function) (Cole and
Stacy, 1987; Pipas, 1985; Tornow and Cole, 1983; Tornow
et al., 1985), and a C-terminal fragment of T-ag relieved the
Ad replication block in monkey cells (hf function) (RabsonFig. 3. Genetic differences between SV40 strains compared in hamsters. Top row:
Human isolate SVCPC contains a simple (archetypal) regulatory region without
changes in the C-terminal variable domain of SV40 large tumor antigen (T-ag). T
622 to the end (residue 709 or 711). The numbering is according to the system for
indicate the position and type of amino acid changes relative to SV40–776. Botto
antigen (t-ag) (white box). The darkened portion represents the amino-terminal am
system for SV40–776. Arrows indicate the position and type of amino acid chanet al., 1964; Kelly and Lewis, 1973; Grodzicker et al., 1974;
Cole et al., 1979; Spence et al., 1990). Virions produced by
the hr/hf mutants fail to assemble properly, apparently due
to an inability to add VP1 to the 75S assembly intermediates
(Spence and Pipas, 1994).
Strains VA45–54 and SVCPC differ by one residue in the
unique region of small t-ag. Small t-ag is not required for
SV40 transformation of most rodent cells (Sa´enz-Robles et
al., 2001; Sullivan and Pipas, 2002), although it is necessary
in Chinese hamster lung cells when the cells are in a resting
state at the time of infection (Martin et al., 1979). Its
expression is required for transformation of primary human
cells by large T-ag (Hahn et al., 2002; Yu et al., 2001), dueDNA sequence profiles of the regulatory regions of the two SV40 isolates.
duplications in the enhancer region. Middle row: Schematic of amino acid
he rectangular boxes represent the T-ag C-terminal region from amino acid
SV40–776 (the variable domain is residues 622–708 in SV40–776). Arrows
m row: Schematic of amino acid changes in the unique region of small t-
ino acids of t-ag in common with T-ag. The numbering is according to the
ge relative to SV40–776.
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phosphatase 2A (PP2A). However, the residue dissimilar
between VA45–54 and SVCPC (position 104) has not been
identified as crucial in binding PP2A (Rundell and Parakati,
2001). The two SV40 strains used in this study also differ in
their regulatory regions. Strain VA45–54 has two 72-base-
pair enhancer elements and SVCPC has only one. In vitro
studies have shown that an enhancer duplication in the
regulatory region of SV40 improves the growth of the virus
in monkey kidney cells in tissue culture (Lednicky and
Butel, 1997; O’Neill et al., 2003).
All the recognized DNA and RNA tumor viruses establish
chronic infections in their natural hosts, with cancer develop-
ment occurring after a lengthy period of viral persistence
(Butel, 2000). It is unclear if SV40 undergoes limited
replication in hamsters. It was reported that SV40 failed to
multiply in the brains of newborn hamsters following
intracerebral inoculation, with residual viral infectivity
undetectable by 26 days post-inoculation (Gerber and
Kirschstein, 1962). No infectious SV40 was detected in the
blood, urine, feces, or mouth swabs of tumor-bearing
hamsters months after inoculation as newborns (Girardi et
al., 1962). When animals were inoculated subcutaneously as
newborns and the virus content of 10% suspensions of
various organs determined periodically over the following
weeks, no infectious virus was detected beyond 10 days post-
inoculation (Black and Rowe, 1964). However, it is ques-
tionable whether those experiments, all of which relied on the
appearance of cytopathic effects in tube cultures of green
monkey kidney cells to measure SV40, would have detected
low-level virus replication in a few susceptible cells in the
hamsters. In contrast to lack of virus replication in young
hamsters in vivo, SV40 multiplication reportedly occurred in
primary cultures of both embryonic and weanling hamster
kidney cells for at least 2–3 months (Black and Rowe, 1963).
Secondary cultures of Chinese hamster kidney cells were
susceptible to SV40 virus infection, and although that
susceptibility was lost with subsequent in vitro subcultures,
the cells remained susceptible to viral DNA infection
(Lavialle et al., 1976). Small amounts of infectious virus
were produced, with very few cells being virus-producing.
There have been reports that infectious virus rarely can
be recovered from extracts of SV40-induced hamster
tumors, but that virus can sometimes be recovered if intact,
viable tumor cells are cultured in contact with susceptible
monkey kidney cells and that recovery of SV40 is more
frequent if tumor cells are fused with monkey cells using
inactivated Sendai virus (Black and Rowe, 1964; Boyd and
Butel, 1972; Diamandopoulos and Carmichael, 1983;
Gerber, 1966; Gerber and Kirschstein, 1962; Girardi et al.,
1962; Kit et al., 1968; Sabin and Koch, 1963; Sol and van
der Noordaa, 1977). A carrier state, in which a low
proportion of cells would continually yield virus, was ruled
out by isolating single cell clones from a transformed
hamster cell line in the presence of SV40 antiserum and then
showing that most clonal cell lines could yield infectiousSV40 (Black, 1966). SV40-transformed cells could also be
induced to yield virus by treatment with DNA-damaging
agents, such as X-ray (Sabin and Koch, 1963), mitomycin
C, UV-irradiation, and g-irradiation (Kaplan et al., 1975).
Further, SV40 could be recovered following transfection of
cellular DNA from transformed hamster cells into monkey
cells using DEAE–dextran (Boyd and Butel, 1972) and
small amounts of free viral DNA could be detected in some
transformed cell lines (Daya-Grosjean and Monier, 1978).
In this study, most SV40-infected hamsters produced
antibodies to T-ag, even in the absence of overt tumors. The
presence of the T-ag antibodies could be explained by
replication of SV40 or by the presence of undetectable
micro-tumors in the animals. It is possible, but unlikely, that
the T-antibody in the non-tumor-bearing hamsters reflected
a response to T-ag in cells abortively infected soon after
inoculation that neither produced virus nor became trans-
formed as the T-antigen antibody persisted for 8–12 months.
We favor the hypothesis that limited virus replication is
possible in some unidentified hamster cells.
We do not believe that the findings of this study reflect
differences in the amount of infectious virus inoculated
between VA45–54 and SVCPC. The plaque assays were
held for up to 18 days, allowing time for any slower-
appearing plaques to become visible and ensuring accurate
titrations of the infectivity of the virus stocks. Errors in
preparation of viral inocula were ruled out by the
reproducibility of results from independent experiments
initiated 1 year apart. The induction of durable antibodies
directed against T-antigen were similar in frequency and
titer among non-tumor-bearing animals that had received
VA45–54 or SVCPC, suggesting that similar amounts of
infectious virus had been inoculated.
It is of interest that not all the hamsters inoculated with a
high dose (107 plaque-forming units) of SV40 produced
enduring levels of neutralizing antibody, although all the
tumor-bearing animals did. More of the non-tumor-bearing
hamsters inoculated with SVCPC had neutralizing antibody
at the termination of the experiments than did those injected
with VA45–54. It has been reported previously that 14% of
non-tumor-bearing animals inoculated at early ages (7 days, 1
month) with 106 tissue culture infectious doses (TCID50) of
SV40 strain VA45–54 had neutralizing antibody 13 months
later (Girardi et al., 1963), whereas 25% of the tumor-bearing
animals from that experiment had detectable neutralizing
antibody. Ashkenazi and Melnick (1963) noted that 44% of
tumor-bearing hamsters inoculated as newborns with about
106 TCID50 of SV40 had viral neutralizing antibody. Black
and Rowe (1964) observed that most tumor-bearing hamsters
inoculated as 2-day-old animals with about 106 TCID50 of
SV40 strain 777 developed neutralizing antibodies after
tumor appearance and that there was a correlation between
median tumor size and neutralizing antibody titer. [Strain 777
is in the same SV40 genogroup as SVCPC (Forsman et al.,
2004).] All three of those studies measured neutralizing
antibody by inhibition of SV40 CPE using 30–300 (Ashke-
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and Rowe, 1964) TCID50 of SV40, a less sensitive method
than the plaque reduction assay used here.
Findings from previous reports together with those from
the current study are compatible with the idea that
differences in the virus–host interaction between VA45–
54 and SVCPC are genetically determined. Perhaps a
faster-replicating nonarchetypal virus, such as VA45–54, is
cleared by the host’s anti-viral immune response more
efficiently than a slower-replicating archetypal strain, such
as SVCPC. In fact, recent evidence from the lymphocytic
choriomeningitis virus model indicates that the speed of
viral replication, through its effect on the host cellular
immune response, influences virus persistence as slower-
replicating virus is more apt to evade immune surveillance
and persist (Bocharov et al., 2004). Poorer clearance and
more common residual persistent infection with SVCPC
(compared to VA45–54) might account for both a higher
frequency of subsequent tumor development and an
increased prevalence of detectable neutralizing antibody
among non-tumor-bearing animals months after virus
inoculation. Periodic production of capsid antigen, whether
or not infectious virus is produced, might be necessary for
the maintenance of neutralizing antibody. Otherwise, anti-
body might wane over time to undetectable levels. To
address this hypothesis, it will be necessary to identify
which cell types may become persistently infected by
SV40 in the hamster.
The present data do not reveal whether a given
histological type of neoplasm can be induced more readily
by a particular SV40 strain, as no significant morphologic
differences were observed in the tumor types in animals
infected with VA45–54 or SVCPC. The high incidence of
mesotheliomas and sarcomas produced by intraperitoneal
inoculation of SV40 in this study most likely signifies the
enhanced susceptibility of the rapidly dividing mesenchy-
mal cells to the oncogenic properties of SV40 in hamsters.
Previous studies also observed a high incidence of
malignant mesotheliomas in hamsters after intracardiac
and intrapleural space inoculations with SV40 (Cicala et
al., 1993). Further studies with additional SV40 strains are
necessary to establish whether any viral genotype displays a
preferential association with a specific tumor type.
In conclusion, the present study indicates that there are
differences in the biological properties of SV40 strains in
vivo, as durable neutralizing antibodies and malignancies
occurred more frequently among animals infected with
SVCPC than with VA45–54. Future studies involving the
use of recombinant viruses will help identify the genomic
region(s) that contain determinants of tumorigenicity. Addi-
tional strains should be characterized to determine the range
in oncogenic properties and the dynamics of viral patho-
genesis among different SV40 genotypes. One implication of
these findings is that the risk of cancer development in
humans may depend, in part, on the viral strain causing an
infection.Materials and methods
Experimental animals
Outbred weanling hamsters that belonged to the HSD:HA-
N:AURA stocks of Syrian golden hamsters (M. auratus)
were purchased from Harlan Sprague Dawley (Indianapolis,
IN). Animals were housed in the biohazard facility at the
Center for Comparative Medicine at Baylor College of
Medicine, Houston, TX, which is accredited by the Associ-
ation for the Assessment and Accreditation of Laboratory
Animal Care. The studies were approved by the Institutional
Animal Care and Use Committee at Baylor College of
Medicine and animals were maintained in compliance with
relevant federal regulations, guidelines, and policies.
Viruses
SV40 strains VA45–54, originally isolated from monkey
kidney cells (Sweet and Hilleman, 1960), and SVCPC,
isolated from a primary brain cancer from a 4-year-old child
(Lednicky et al., 1995) and detected in different human
malignancies (Arrington et al., 2004; Krieg et al., 1981;
Vilchez et al., 2002a, 2002b), were used. The two strains are
from different phylogenetic genogroups (Forsman et al.,
2004). Differences in the regulatory regions and the large
and small tumor antigens of the two strains are shown (Fig.
3). Virus stocks were prepared at 37 8C by inoculating
confluent monolayers of TC-7 cells at a multiplicity of
infection of 0.01 plaque-forming units per cell. When
cytopathic effects involved 75–100% of the cells, the
cultures were disrupted by three cycles of quick freezing
and thawing, the cell lysates were clarified by low-speed
centrifugation, and the supernatant fluids were stored at 70
8C. Virus assays were performed using TC-7 cells as
described previously (Boyd and Butel, 1972). Assays were
held for up to 18 days, at least 2 days beyond the time
maximum plaque counts were attained.
Induction of tumors in hamsters
Using aseptic techniques, 21-day-old male and female
experimental animals were injected by the intraperitoneal
route with 1.0  107 plaque-forming units of virus in 0.5 ml.
Control animals of the same age and sex as SV40-infected
hamsters were inoculated with 0.5 ml of uninfected TC-7
cell lysates. Animals were observed by the investigators at
least three times per week for evidence of illness or tumor
formation. Two independent experiments were carried out,
one of 8 months and one of 12 months duration.
Detection of SV40 T-ag antibodies
Antibody to SV40 T-ag was detected in the sera of SV40-
infected and control animals by indirect immunofluores-
cence staining of T-ag-expressing transformed cells as
R.A. Vilchez et al. / Virology 330 (2004) 168–177 175described (Butel and Ozbun, 1994). Ascites fluid from an
SV40 tumor-bearing hamster was the source of control
positive antisera against SV40 T-ag.
Serum neutralization assays
A specific plaque-reduction test was performed to detect
and quantitate SV40 neutralizing antibodies in the sera of
experimental animals as previously described (Butel et al.,
1999b). Serum samples from infected and control animals
were tested in triplicate. Initial screening assays involved a
final serum dilution of 1:10 or 1:20; positive samples that
reduced the number of plaques by 50% or more as
compared with the normal hamster control were titered in
repeat experiments.
Pathology and immunohistochemistry
Two groups of hamsters from SV40-infected and their
respective control groups were sacrificed under aseptic
conditions at 8 and 12 months post-inoculation or when
there was evidence of neoplasia or debility. Euthanasia was
via isoflurane overdose and exsanguination by cardiac
puncture. Necropsy included gross examination and
collection of all organs and neoplasms. Tissues were fixed
in 10% neutral buffered formalin or zinc formalin,
trimmed, and processed into paraffin blocks, sectioned at
5 Am, stained with hematoxylin and eosin, and evaluated
microscopically. Immunohistochemical analysis of paraffin
sections of paraformaldehyde-fixed tumor tissue was
performed by the avidin–biotin complex technique. Speci-
men slides were steamed for 20 min in 10 mM citric buffer
(pH 6.0) for antigen retrieval prior to incubation with
antibody for detection of SV40 T-ag. Mouse monoclonal
antibodies against the N-terminus (PAb416, Oncogene
Research Products, San Diego, CA) or C-terminus
(PAb101, Santa Cruz Biotechnology Inc., Santa Cruz,
CA) of SV40 T-ag were incubated with deparaffinized
sections at room temperature for 1 h. Both antibodies were
used at a dilution of 1:100, as recommended by the
manufacturers. Slides were washed with Tris-buffered
saline (TBS) with Tween 20 (Signet Laboratories, Inc.,
Dedham, MA), followed by 20 min incubation with
secondary antibodies, DAKO EnVision Peroxidase anti-
mouse IgM and IgG (DAKO Corp.). After sections were
washed three times with TBS, liquid diaminobenzidine
(DAB) substrate was applied, following the manufacturer’s
(DAKO) instructions. Sections were counterstained with
Mayer’s modified hematoxylin.
Virus rescue
Tumor samples were removed aseptically from hamsters,
dissociated using trypsin, and cultured using DMEM media
containing 10% fetal bovine serum. A flask culture of cells
was subjected to three cycles of freezing and thawing, andthe lysates were clarified by low-speed centrifugation.
Clarified tumor cell line lysates were analyzed by plaque
assay, plaques were picked, and virus stocks prepared in
TC-7 cells (described above).Acknowledgments
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